Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution

Dong Ryeol Lee,1,2 Ji Su Park,1 Il Hak Bae,1 Yan Lee,1 B Moon Kim1 1Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea; 2Technology Development Center, BASF Company Ltd., Hwaseong, Gyeonggi-do, Republic of Korea Abstract: Liquid crystal nanopa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee DR, Park JS, Bae IH, Lee Y, Kim BM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	LCNP PIT Sustained release Bioavailability Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a2efe62370d04c838938ea321c57733c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2efe62370d04c838938ea321c57733c
record_format	dspace
spelling	oai:doaj.org-article:a2efe62370d04c838938ea321c57733c2021-12-02T06:46:24ZLiquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution1178-2013https://doaj.org/article/a2efe62370d04c838938ea321c57733c2016-03-01T00:00:00Zhttps://www.dovepress.com/liquid-crystal-nanoparticle-formulation-as-an-oral-drug-delivery-syste-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Dong Ryeol Lee,1,2 Ji Su Park,1 Il Hak Bae,1 Yan Lee,1 B Moon Kim1 1Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea; 2Technology Development Center, BASF Company Ltd., Hwaseong, Gyeonggi-do, Republic of Korea Abstract: Liquid crystal nanoparticles have been utilized as an efficient tool for drug delivery with enhanced bioavailability, drug stability, and targeted drug delivery. However, the high energy requirements and the high cost of the liquid crystal preparation have been obstacles to their widespread use in the pharmaceutical industry. In this study, we prepared liquid crystal nanoparticles using a phase-inversion temperature method, which is a uniquely low energy process. Particles prepared with the above method were estimated to be ~100 nm in size and exhibited a lamellar liquid crystal structure with orthorhombic lateral packing. Pharmacokinetic and tissue distribution studies of a hydrophobic peptide-based drug candidate formulated with the liquid crystal nanoparticles showed a five-fold enhancement of bioavailability, sustained release, and liver-specific drug delivery compared to a host–guest complex formulation. Keywords: LCNP, PIT, sustained release, bioavailabilityLee DRPark JSBae IHLee YKim BMDove Medical PressarticleLCNPPITSustained releaseBioavailabilityMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss Issue 1, Pp 853-871 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	LCNP PIT Sustained release Bioavailability Medicine (General) R5-920
spellingShingle	LCNP PIT Sustained release Bioavailability Medicine (General) R5-920 Lee DR Park JS Bae IH Lee Y Kim BM Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
description	Dong Ryeol Lee,1,2 Ji Su Park,1 Il Hak Bae,1 Yan Lee,1 B Moon Kim1 1Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea; 2Technology Development Center, BASF Company Ltd., Hwaseong, Gyeonggi-do, Republic of Korea Abstract: Liquid crystal nanoparticles have been utilized as an efficient tool for drug delivery with enhanced bioavailability, drug stability, and targeted drug delivery. However, the high energy requirements and the high cost of the liquid crystal preparation have been obstacles to their widespread use in the pharmaceutical industry. In this study, we prepared liquid crystal nanoparticles using a phase-inversion temperature method, which is a uniquely low energy process. Particles prepared with the above method were estimated to be ~100 nm in size and exhibited a lamellar liquid crystal structure with orthorhombic lateral packing. Pharmacokinetic and tissue distribution studies of a hydrophobic peptide-based drug candidate formulated with the liquid crystal nanoparticles showed a five-fold enhancement of bioavailability, sustained release, and liver-specific drug delivery compared to a host–guest complex formulation. Keywords: LCNP, PIT, sustained release, bioavailability
format	article
author	Lee DR Park JS Bae IH Lee Y Kim BM
author_facet	Lee DR Park JS Bae IH Lee Y Kim BM
author_sort	Lee DR
title	Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
title_short	Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
title_full	Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
title_fullStr	Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
title_full_unstemmed	Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
title_sort	liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/a2efe62370d04c838938ea321c57733c
work_keys_str_mv	AT leedr liquidcrystalnanoparticleformulationasanoraldrugdeliverysystemforliverspecificdistribution AT parkjs liquidcrystalnanoparticleformulationasanoraldrugdeliverysystemforliverspecificdistribution AT baeih liquidcrystalnanoparticleformulationasanoraldrugdeliverysystemforliverspecificdistribution AT leey liquidcrystalnanoparticleformulationasanoraldrugdeliverysystemforliverspecificdistribution AT kimbm liquidcrystalnanoparticleformulationasanoraldrugdeliverysystemforliverspecificdistribution
_version_	1718399769637814272

Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution

Ejemplares similares